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Abstract
Background: Immune reconstitution inflammatory syndrome (IRIS) is an important complication of HAART in sub-
Saharan Africa, where opportunistic infections (OIs) including mycobacteria and cryptococcus are common. The
immune system’s role in HIV infected patients is complex with cytokine expression strongly influencing HIV
infection and replication.
Methods: We determined the expression patterns of 10 cytokines by Luminex multi-analyte profiling in 17 IRIS
nested case-control pairs participating in a prospective South African cohort initiating anti-retroviral therapy.
Results: Interferon-gamma (IFN-g) expression was significantly elevated in IRIS cases compared to controls (median
9.88 pg/ml versus 2.68 pg/ml, respectively, P = 0.0057), while other cytokines displayed non-significant differences
in expression. Significant correlation was observed between IL-6, IL-10, and IFN-g expression in the IRIS patients.
Conclusions: Significantly increased expression levels of IFN-g suggest that this cytokine possibly plays a role in
IRIS pathology and is a potential diagnostic marker.
Background
HIV infection leads to a progressive loss of CD4+ T cells
and eventually to the onset of AIDS [1]. Highly active
antiretroviral therapy (HAART) results in a dramatic
reduction in AIDS-defining illnesses and mortality by
inhibiting HIV replication with the subsequent recovery
of CD4+ T cell numbers and the restoration of immune
function [2-4]. Some patients experience immune recon-
stitution inflammatory syndrome (IRIS), or immune
restoration disease (IRD), as a result of pathological
responses induced during immune restoration following
the initiation of HAART [5,6]. IRIS is characterized by a
paradoxical worsening of a pre-existing, or unmasking
of a previously sub-clinical infection in the first weeks of
HAART [7]. The immune response that causes IRIS is
both excessive and unregulated, as the rapid restoration
of immune function after initiating HAART leads to
upregulated cell-mediated responses to live or dead
infectious organisms or to antigens [2,8]. The resultant
inflammation causes symptoms which can be severe.
The presence of antigenic stimulus, whether infectious
or non-infectious, is reportedly a pre-requisite to devel-
oping IRIS, and the incidence of IRIS is likely to be
dependent on the underlying infectious burden [9,10].
In South Africa, where an estimated 5.2 million people
live with HIV [11], the incidence of IRIS is reported to
be 25.1 IRIS cases/100 person years [10].
The spectrum of IRIS symptoms is diverse and
depends on the pathogen involved, complicating the
diagnosis of IRIS [2,12]. Infectious pathogens that are
often implicated in the syndrome include cryptococcus,
Mycobacterium Tuberculosis, varicella zoster, herpes
virus, Kaposi’s sarcoma and cytomegalovirus (CMV)
[2,9]. IRIS-associated morbidity can be considerable and
may result in increased hospitalization rates, further
increasing the burden of HIV in resource-poor settings
where health-care facilities are already stretched to max-
imum capacity, particularly in countries with a high
tuberculosis burden [5]. Because of the associated mor-
bidity, and sometimes mortality, it is important to diag-
nose and treat IRIS in a timely fashion.
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The pathogenesis of IRIS is not well understood.
Although what is clinically noted is the excessive and
unregulated immune response, there is no common
immunological pathway and different processes seem to
drive the different expressions of IRIS [2]. HIV infection
itself can also provoke IRIS [5,13]. Numerous members
of the cytokine network are integrally involved in regu-
lating the replication of HIV as well as several steps of
the HIV life cycle [14]. It therefore stands to reason that
several cytokines may be involved in the pathogenesis of
IRIS. As various cytokines possess the ability to regulate
the production of other cytokines, their combined effect
is often greater than the function of a single component
[15]. This study was conducted to increase our under-
standing of the immunopathogenesis of IRIS by compar-
ing cytokine profiles in IRIS patients and controls, and
by identifying which cytokine markers contribute to the
increased immune activation observed in these patients,
The Bio-Plex system, which makes use of Luminex
multi-analyte profiling technology allows for the analysis
of many different cytokines in a single microtiter well.
Using this technology, we were able to identify the cyto-
kine profiles involved in some IRIS-related illnesses in
South African patients, as well as identifying the com-
monalities and differences in their cytokine expression
profiles.
Methods and materials
Study Population
This nested case-control study was a sub-study of a pro-
spective longitudinal South African cohort monitored to
determine IRIS incidence during the first 6 months of
HAART treatment. HAART initiation was in accordance
with the 2007 South African National Antiretroviral
Treatment Guidelines, which define treatment initiation
criteria as CD4+ cell count ≤200 cells/ml or WHO stage
IV AIDS-defining illness [10,16]. Adult patients (> 18
years) recruited in the study were HAART-naïve at the
time that therapy was started at Johannesburg Hospital
HIV clinics in 2006 and 2007. Enrolment into the study
required willingness to provide written consent for addi-
tional blood draw and sample storage. Cases required
signs and symptoms of IRIS (see IRIS case definition
below). Cases and controls were HAART-duration
matched in a 1:1 ratio. Ethics approval was obtained
from all participating institutions. 17 case-control pairs
took part in this study.
Ethics approval
University of the Witwatersrand HREC M050347; Uni-
versity of North Carolina at Chapel Hill Biomedical IRB
05-1603; Duke University IRB Pro00003782.
Immune reconstitution inflammatory syndrome case
definition
IRIS is generally defined as a paradoxical clinical wor-
sening due to a subclinical opportunistic or previously-
treated pathogen as a result of an adequate response to
HAART [10,17]. For ‘unmasking’ IRIS, a new localized
infection was required from a focal inflammatory pro-
cess (suppurative lymph node, pulmonary infiltrate,
positive CSF culture, etc.) in a patient with no pre-exist-
ing evidence of this infection prior to HAART despite a
thorough clinical and diagnostic evaluation. For the
‘paradoxical’ form of IRIS, a patient needed to be diag-
nosed and treated for an OI prior to HAART initiation.
Following HAART, the patient experienced a clinical
worsening (worsening lymphadenopathy or suppuration,
expansion of Kaposi’s lesions, recurrence of meningeal
signs and symptoms) at the original or new site of infec-
tion accompanied by systemic symptoms of inflamma-
tion. In all cases, a thorough diagnostic evaluation
confirmed the absence of other identifiable pathogens.
For this immunological analysis, only confirmed IRIS
cases (i.e. an identifiable pathogen in the setting of a
documented adequate HAART response, defined as >1
log10 reduction in the baseline HIV RNA level) and
their controls (matched for duration of HAART within
a two week window) were eligible, resulting in a total
sample size of 17 case-control pairs.
Data collection and measurement of plasma cytokines
Plasma samples were collected from 17 HIV-infected
IRIS cases and 17 matched controls prior to the admin-
istration of any anti-inflammatory agents. EDTA-sepa-
rated plasma was stored at -20°C until analysis. Ten
cytokines (IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70,
IL-13, IFN-g, and TNF-a) were analysed using a Human
Cytokine 10-Plex Th1/Th2 assay (Bio-Rad, California,
USA) and Luminex multi-analyte profiling technology
(Bio-Rad, USA) according to manufacturer instructions.
Plasma samples were thawed in a 37°C waterbath and
diluted 1 in 4 with sample diluent, while standards were
reconstituted in standard diluent. Eight standards were
made in duplicate by serial dilution, with each standard
being a 4-fold dilution of the previous standard. Stan-
dards and samples were incubated with the coupled
magnetic beads in a multi-well plate for 1 hour at room
temperature. Following this, detection antibody was
added to each standard and sample, and a further 30
minute incubation period was observed. Streptavidin-PE
was used as the fluorochrome for antibody detection.
Using Bio-Plex Manager software version 5.0, standard
Luminex maintenance procedures were performed, and
Bio-Plex CAL1 and CAL2 beads were used to calibrate
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the system. A new protocol was prepared and standard
information was entered for each cytokine tested. Sam-
ple information was entered; all standards and samples
were assayed concurrently, on the same plates, in order
to avoid intra-assay variability.
Statistical analysis
Median cytokine expression levels of IRIS cases were
compared to non-IRIS controls. Nonparametric Spear-
man correlation was applied to quantify the relation-
ships between IFN-g, IL-6, and IL-10 cytokine
responses. P values less than 0.05 were considered sig-
nificant. All statistical analyses were performed using
GraphPad Prism version 4.0 for Windows (GraphPad
Software, San Diego, California, USA).
Results
Description of study participants
As reported previously by Murdoch et al. (2009), IRIS
cases had a significantly lower baseline CD4+ count at
the initiation of HAART compared to matched non-
IRIS controls (79 versus 132 cells/mm3, respectively, P =
0.02). This is in keeping with other studies where low
baseline CD4+ T-cell counts were a risk factor for devel-
oping IRIS [10,18]. HIV RNA levels at baseline and at
sampling were similar between IRIS and non-IRIS con-
trol groups [17]. This is unexpected as viral load usually
correlates with immune activation which potentially
feeds cytokine production [19]. The median time inter-
val between HAART initiation and the development of
IRIS was 38 days (interquartile range 24-56 days), with
blood sampling for immunological analysis occurring on
average one week after IRIS diagnosis and clinical eva-
luations were complete.
IRIS cases exhibited a range of manifestations. These
included nontuberculous lymphadenitis (n = 1), follicular
facial rash (n = 1), bacterial scalp abscess (n = 1), genital
herpes (n = 1), lip zoster (n = 2), abdominal TB (n = 2),
Kaposi’s sarcoma (n = 1), pulmonary TB (n = 3), TB ade-
nitis (n = 2), and cryptococcal meningitis (n = 3).
Plasma pro- and anti-inflammatory cytokine
concentrations differ between IRIS patients and non-IRIS
controls
Luminex analysis revealed differences in the cytokine
concentration levels between IRIS cases and non-IRIS
controls within each disease manifestation. IL-1b was
below the levels of detection of the Luminex and was
excluded from further analyses. Overall, most IRIS cases
exhibited significantly increased IFN-g expression com-
pared to non-IRIS controls (median 9.88 pg/ml versus
2.68 pg/ml, respectively, P = 0.0057) (Figure 1). Most
IRIS cases also demonstrated increased but non-signifi-
cant elevations of IL-6 (IRIS case median 11.38 pg/ml
versus Non-IRIS 2.80 pg/ml, P = 0.2114) and IL-10 (IRIS
case median 1.21 pg/ml versus Non-IRIS 1.02 pg/ml, P =
0.5751) (Figure 1). Marginal and non-significant increases
in expression were detected in IL-5 and IL-12, while
slight decreases were noted in IL-1b, IL-2, IL-4, IL-13,
and TNF-a in IRIS patients (Figure 1). In general, most
IRIS patients showed an increase in IL-6 and IFN-g in
comparison to non-IRIS controls (see Table 1).
When comparing cytokine levels between IRIS cases and
non-IRIS controls by the type of IRIS presentation, different
cytokine expression patterns were observed but numbers of
cases were too small for statistical sub-group analysis.
While most IRIS cases showed an increase in IL-6 and
IFN-g in comparison to non-IRIS controls (see Table 1), it
is evident that each opportunistic illness exhibited a unique
cytokine profile. IRIS cases with bacterial scalp abscess or
genital herpes had decreased IL-6 compared to their non-
IRIS controls. In the IRIS patient that presented with Kapo-
si’s sarcoma, increases in IL-6, IL-10, IL-12, IL-13 and IFN-
g expression were shown (Table 1). All TB patients had
increases in IL-6 and IFN-g, with TB adenitis cases also
showing an increase in IL-10 expression. Pulmonary TB
also showed and increase in IL-5 and TNF-a. Although it
seemed that both IL-6 and IFN-g were increased in most
IRIS patients in comparison to non-IRIS controls, only
IFN-g showed a significant difference in expression between
IRIS patients and non-IRIS controls (Figure 1).
Given the likelihood that complex cytokine expression
profiles are present in immunological responses such as
IRIS, correlation analyses were performed. Within IRIS
cases, there were significant correlations between IL-6,
IL-10 and IFN-g expression over the range of conditions
studied (P < 0.05) (Figure 2).
Figure 1 Levels of relative changes in cytokine expression in
IRIS patients compared to HAART-duration matched controls.
Nonsignificant elevations in expression levels are seen in IL-5, IL-6,
and IL-10, whereas IFN-g expression is significantly increased in IRIS
patients. The other cytokine expression levels do not vary noticeably
between IRIS patients and controls.
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Discussion
It is difficult to try and postulate the mechanisms that
could lead to clinical IRIS, as the balance between pro-
and anti-inflammatory cytokines is at the root of both
HIV disease and IRIS. In this immunological analysis,
IFN-g expression was significantly elevated in IRIS cases
compared to non-IRIS controls matched for HAART
duration. This observation is in accordance with what
has previously been reported in that the initiation of
HAART results in a shift from a Th2 to a Th1 cytokine
profile, which may lead to an increase in IFN-g expres-
sion [20]. Elliot et al. 2009 also observed greater
increases in IFN-g in TB-IRIS patients compared with
non-TB-IRIS controls on HAART. IFN-g expression was
significantly increased in the IRIS patients in our study
in the majority of cases, most notably in those exhibiting
nontuberculous- and TB-lymphadenitis, lip zoster,
abdominal or pulmonary TB, Kaposi’s sarcoma, and
cryptococcal meningitis. This increase in IFN-g may be
due to increased numbers of circulating T-cells that
produce IFN-g when they are stimulated with pathogen-
specific antigens, which has previously been reported in
patients with TB or cryptococcal IRIS [5,15].
Although this study was limited in terms of small
sample number, some heterogeneity in cytokine
responses was observed between the different IRIS OIs.
We hypothesize that this may indicate a host-pathogen
interaction in determining the immunopathology of
IRIS. In addition, we observed an elevation of IL-6
expression in most IRIS cases. IL-6 is believed to play a
role in the development of the inflammatory response
during immune restoration and may act as a marker for
Table 1 Relative cytokine expression patterns of opportunistic infection-related IRIS cases compared to matched
controls.
Infectious disease IL-1b IL-2 IL-4 IL-5 IL-6 IL-10 IL-12 IL-13 IFN-g TNF-a
Nontuberculous lymphadenitis (n = 1) E D E E E E E D I E
Follicular facial rash
(n = 1)
E E E I E D E E E E
Bacterial scalp abscess (n = 1) E E D E I E E D D D
Genital herpes (n = 1) E E E D E E E E D E
Lip zoster
(n = 2)
E E E E I E E E I E
Abdominal TB (n = 2) E E E E I E E E I E
Kaposi’s sarcoma (n = 1) E E E E I I I I I D
Pulmonary TB (n = 3) E E E I I E E E I I
TB adenitis
(n = 2)
E E E E I I E E I E
Cryptococcal meningitis
(n = 3)
E E E I I E E E I E
Each disease manifestation exhibited a unique cytokine expression profile. I = relative increases in cytokine expression in IRIS cases compared to Non-IRIS
controls, E = equivocal expression compared to Non-IRIS controls, and D = relative decreases in expression compared to Non-IRIS controls.
Figure 2 Correlation between IL-6, IL-10, and IFN-g. The correlations between IL-6, IL-10 and IFN-g concentrations in IRIS patients were
significant.
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persistent immune activation [21]. In our study, IRIS
cases produced higher amounts of IL-6 than non-IRIS
controls, but it is unclear whether this is a consequence
or a cause of the IRIS.
IL-10 expression was also increased in IRIS cases
compared to non-IRIS controls, although this observa-
tion did not reach statistical significance. IL-10 has
many suppressor functions including the inhibition of
pro-inflammatory cytokine production and the inhibi-
tion of dendritic cell expression of co-stimulatory mole-
cules [6]. IL-10 is known to suppress IFN-g production
and immune responses to mycobacterial antigens [22]
and has been postulated to be deficient in IRIS indivi-
duals, leading to a Th1 predominant cytokine profile
responsible for the clinical manifestations of IRIS [18].
Impairment of IL-10 production despite an expansion of
T regulatory cells (Tregs) has also been observed in
immune responses to atypical mycobacterial antigens
[23]. Our finding of increased IL-10 levels in IRIS
patients may suggest that the pathogenesis of IRIS is
not simply due to a scarcity of immunoregulatory cyto-
kines resulting in an overactive inflammatory response.
Rather, this observation could suggest that the exuber-
ant pro-inflammatory antigenic response that charac-
terizes IRIS occurs first, followed by a compensatory
increase in IL-10.
This is an interesting observation in light of the recent
reports of expanded numbers of regulatory T cells
(Tregs) in HIV [24-29]. While there are some scenarios
that would incorporate our understanding of immune
activation as a hallmark of progressive HIV infection
together with the inflammatory manifestations of IRIS
[30], our finding of elevated IL-10 supports the hypoth-
esis that a vigorous pro-inflammatory response is the
primary trigger of both the symptoms of progressive dis-
ease as well as IRIS manifestations. Elevations in regula-
tory cells and cytokines would be a compensatory
secondary event. Also, as regulatory T cells are thought
to act largely via cell-cell interaction rather than cyto-
kine secretion, interpretation of IL-10 as a suppressor
cytokine may be limited to certain subsets of Tregs
(such as induced, rather than natural Tregs) [30,31].
The correlation between IL-6, IL-10, and IFN-g may
be due to common pathways of action. IL-6 and IL-10
both signal through the JAK1-STAT3 pathway, although
there is a lack of understanding of how specificity in
gene expression is determined by the two different
receptors [32,33]. IL-10 reportedly functions to inhibit
the inflammatory responses from activated macrophages
and dendritic cells, and may even prevent the clearance
of pathogens [32,33]. Yet other STAT3-activating recep-
tors, such as IL-6, do not seem to activate the same
anti-inflammatory response [33]. This may be because
the IL-10 receptor activates STAT3 in a SOCS3
(suppressor of cytokine signaling 3)-independent man-
ner, while IL-6 receptor activation of STAT3 requires
SOCS3 modulation [33]. SOCS3 seems to be one of the
regulatory molecules in the process of JAK1-STAT3
activation, but better delineation of the JAK-STAT sig-
naling pathway is needed to fully understand how differ-
ent cytokines control the expression of different genes
through this signaling pathway.
This immunological study had a number of limita-
tions. Although in the initial study we recruited one of
the largest prospective IRIS cohorts to date, the overall
number of confirmed IRIS cases was limited with only a
few case-control pairs in each subgroup analysis. To
better characterize potential cytokine-specific immune
responses in IRIS patients, larger sample sizes would be
needed in future studies. We were further limited by the
lack of longitudinal immunological sampling, and it is
important to note differences in cytokine profiles may
be indicative of the timing of immunological sampling
rather than a true difference. Future immunological stu-
dies should collect samples over time and accurately
describe these intervals to allow suitable comparisons
and interpretation. This would contribute to our under-
standing of the syndrome, since immune reconstitution
is a dynamic and not a static observation.
Lastly, while Luminex-based serum assays provide a
wealth of cytokine expression data, we were unable to
conclude which cell types are responsible for our obser-
vations. It is likely that a number of cell types are
involved in the production of cytokines, as immune
activity during HIV infection involves the activation and
proliferation of most immune cell types [19]. Ideal IRIS
immunological studies should also employ flow cyto-
metric assays, such as intracellular staining and stimula-
tion assays to better elucidate the immunopathogenesis.
Conclusions
Consistent with other studies, we observed an increase in
IFN-g production in most individuals experiencing IRIS.
The significant IFN-g increase across most IRIS manifes-
tations suggests its potential use as an overall adjunct
diagnostic marker for the syndrome. However, whether
the measurement of additional cytokines is useful within
specific disease presentations remains unknown. Further
investigation into additional cytokine measurements may
lead to a better understanding of disease-specific manifes-
tations of IRIS, leading to improved diagnosis and man-
agement of this complex condition.
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